

JUNE 4-6, 2026

NAPLES, ITALY
CENTRO CONGRESSI STAZIONE MARITTIMA

5TH INTERNATIONAL 5 DRY EYE CONGRESS

A WORLD OF INNOVATION
FOR THE OCULAR SURFACE

ORGANIZERS:

Luca Vigo, Giovanni Tedesco

PRESIDENTS:

Prof. Ciro Costagliola,
Prof. Francesca Simonelli

SCIENTIFIC COMMITTEE:

Andres Benatti, Paolo Fogagnolo,
Caterina Gagliano, Samer Hamada,
Mina Massaro-Giordano, Cosimo Mazzotta,
Antonio Moramarco, Liliana Nobrega,
Carlos Rocha De Lossada, Rolando Toyos

qp MEETINGS
www.2026dryeyecongress.com

WITH THE PARTICIPATION OF

 DrySpa®

PRELIMINARY PROGRAM



FACULTY

AL-SAATI ANOUD - SAUDI ARABIA
ARIÑO MAYTE - SPAIN
BAGAGLIA SIMONE ALEX - ITALY
BEDEI ANDREA - ITALY
BENATTI ANDRES - ARGENTINA
BOCCUZZI DOMENICO - ITALY
BORRONI DAVIDE - ITALY
BRUZIO SIMONE - ITALY
CARLINI GIANPAOLO - ITALY
CARO MAGDALENO MANUEL - SPAIN
CASTELLINI LAURA - ITALY
CIMINO LUCA - ITALY
CONNAN TAM - UNITED KINGDOM
CONTI LUIGI - ITALY
COSTAGLIOLA CIRO - ITALY
CRAIG JENNIFER P. - NEW ZEALAND
D'ANDREA LUCA - ITALY
D'ESPOSITO FABIANA - ITALY
DE RUVO VALENTINO - ITALY
DEVRIES DOUGLAS K. - USA
DI CARLO IGOR - ITALY
DI GIOVANNI ALFREDO - ITALY
FANTOZZI MARCO - ITALY
FASCIANI ROMINA - ITALY
FERLINI LEONARDO - ARGENTINA
FERRARI GIULIO - ITALY
FLORIO VINCENZO - ITALY
FOGAGNOLO PAOLO - ITALY
FRATINI ANTONIO - UNITED KINGDOM
GAGLIANO CATERINA - ITALY
GALOR ANAT - USA
GESSA MARIA - SPAIN
GIANNACCARE GIUSEPPE - ITALY
GUALDI FEDERICA - ITALY
GUALDI LUCA - ITALY
HAMADA SAMER - UNITED KINGDOM
HAMRAH PEDRAM - USA
HAROUCHE MERIEM - MOROCCO
HERVAS ANA - SPAIN
LANZA MICHELE - ITALY
LAPUENTE CARLOS RUIZ - SPAIN
LO GIUDICE GREGORIO - ITALY
LUNARDON SOFIA - ITALY
MAMMONE MASSIMO - ITALY
MARINO LUIGI - ITALY
MASSARO GIORDANO MINA - USA
MATSOU ARTEMIS - UNITED KINGDOM
MAUBON LAURA - UNITED KINGDOM
MAZZOTTA COSIMO - ITALY
MERAYO JESUS - SPAIN
MODUGNO ALESSANDRA - ITALY
MORAMARCO ANTONIO - ITALY
NOBREGA LILIANA - BRAZIL
ORIONE CARLO - ITALY
PACELLI GIORGIO FRANCESCO - ITALY
PASCOTTO ANTONIO - ITALY
PASSARO MARIA LAURA - ITALY
PEREZ VIKTOR - USA
PISCOPO RAFFAELE - ITALY
PULVIRENTI MANUELA - ITALY
ROCHA DE LOSSADA CARLOS - SPAIN
ROSZKOWSKA ANNA MARIA - ITALY/POLAND
RUSSO FEDELE - ITALY
SAAD MOHAMED - EGYPT
SANNACE CARMELA - ITALY
SANTUCCI CARLO MARIA - ITALY
SCAPAGNINI GIOVANNI - ITALY
SCHIANO LOMORIELLO DOMENICO - ITALY
SIMONELLI FRANCESCA - ITALY
SONEGO SILVIA - ITALY
STRIANESE ALFONSO - ITALY
TEDESCO GIOVANNI - ITALY
TOYOS ROLANDO - USA
TRAVÉ HUARTE SÒNIA - UNITED KINGDOM
TROISI MARIO - ITALY
TROISI SALVATORE - ITALY
VAGGE ALDO - ITALY
VAGNONI ANTONIO - ITALY
VIGO LUCA - ITALY
WEINFURTER SANDRA - ITALY
ZEPPIERI MARCO - ITALY
ZUCCARINI SILVIO - ITALY



THURSDAY, JUNE 4

08.30 OPENING OF THE CONGRESS

09.00 SESSION I:

DRY EYE, CORNEAL DISEASES AND REFRACTIVE SURGERY

Pathophysiology, classification and management of dry eye disease; interactions between corneal pathology and refractive surgery outcomes

MODERATORS: **Vincenzo Florio, Luca Vigo**

PANEL: **Caterina Gagliano, Liliana Nobrega, Andres Benatti, Antonio Moramarco**

09.00 Artificial intelligence in the diagnosis of dry eye – **Alfredo Di Giovanni**

09.08 Hypotonising eye drops and ocular surface – **Carmela Sannace**

09.16 Upper lid meibography: what we knew and what we think now – **Cristina Patricia Pac**

09.24 Biomarkers, diagnostic-therapeutic protocols and physical therapy. Contemporary approach to diagnosis and treatment of DED in compliance with timing and effectiveness – **Igor Di Carlo**

09.32 Allergice eye disease and dry eye eyes – **Tam Connan**



09.40 Nutrition, Nutraceutica Microbiota and Inflammaging: a holistic approach to dry eye – **Giorgio Francesco Pacelli**

09.48 Pediatric dry eye – **Aldo Vagge**

09.56 What's new in immunomodulation for dry eye therapy – **Antonio Moramarco**

10.04 Ocular Surface and Nutraceuticals. Argentine Clinical Data with Patagonian Maqui - **Andres Benatti, Leonardo Ferlini**

10.12 Dry Eye in the Emergency department – **Silvia Sonogo**

10.20 Dry Eye and systemic disease - **Liliana Nobrega**

10.28 Aerosol and the Ocular Surface—Vaping and Dry Eye Disease – **Caterina Gagliano**

10.36 Discussion

10.56 WORKSHOP and COFFEE BREAK

11.26 Dry Eye in keratoplasty: what evidence says - **Carlos Rocha de Lossada**

11.34 Dry eye after infectious keratitis – **Antonio Moramarco**

11.42 Reducing ocular surface disease in glaucoma patients – **Michele Lanza**

11.50 Severe DED leading to corneal perforation. What to do? – **Mohamed Saad**

11.58 Chronic cicatricial conjunctivitis – **Caterina Gagliano**

12.06 Post-vitreectomy dry eye: a prospective study of ocular surface changes and associated risk factors – **Nemer Sayed Ahmad**

12.14 Discussion



12.30 SYMPOSIUM FB VISION

DRY EYE... BEYOND THE OCULAR SURFACE

MODERATOR: **Giovanni Scapagnini, Igor Di Carlo**

12.30 Is dry eye treated only with topical therapy? – **Giovanni Scapagnini**

12.45 Proteases, ocular surface alterations and keratoconus. Therapeutic approach 2.0 – **Cosimo Mazzotta**

13.00 Dry eye in diabetic patients: how to comprehensively manage symptoms. The DIAMOND study – **Giovanni Tedesco**

13.15 Discussion

13.30 BREAK

14.00 SESSION II: INNOVATIONS 1

Novel technologies, AI-based diagnostic tools, new biomarkers, and future perspectives in ocular surface disease management

MODERATORS: **Manuela Pulvirenti, Marco Zeppieri**

PANEL: **Giovanni Tedesco, Luca Vigo, Samer Hamada, Luca Gualdi, Cosimo Mazzotta**

14.00 Dry eye in special cases: diagnosis, management, and current treatment – **Ana Hervas**

14.08 IOL premium and dry eye – **Andrea Bedei**



- 14.16 Phakic IOLs in patients with dry eye – **Luca Gualdi**
- 14.24 Laser presbyopic treatments and dry eye – **Luigi Conti**
- 14.32 Influence of the dry eye on biometrics – **Domenico Schiano Lomoriello**
- 14.40 Smile and Dry Eye – **Marco Fantozzi**
- 14.48 Crosslinking Antiprotease Activity and Dry-Eye, First Clinical Evidences – **Cosimo Mazzotta**
- 14.56 Dry Corneal tunnel and dry eye – **Massimo Mammone**
- 15.04 Discussion

15.24 WORKSHOP GMV and COFFEE BREAK

15.54 SESSION III: ESCRS ACADEMY DRY EYE SYMPOSIUM

PANEL: **Carlos Rocha de Lossada, Artemis Matsou, Laura Maubon**

- 15.54 Preparing the surface for surgical success – **Laura Maubon**
- 16.09 Cataract Surgery in OCP/MMP: Pre-op Control to Post-op Protection – **Artemis Matsou**
- 16.24 Neuropathic pain after corneal refractive surgery – **Carlos Rocha de Lossada**
- 16.39 Discussion



16.54 SESSION II (bis):

INNOVATIONS 2

MODERATORS: **Manuela Pulvirenti, Marco Zeppieri**

PANEL: **Giovanni Tedesco, Luca Vigo, Samer Hamada, Luca Gualdi**

16.54 MMP 9 and OSDI in DED treatments prior in cataract surgery
– **Carlos Ruiz Lapuente**

17.02 Efficacy and advantages of an eyedrop combination of HA and Aloe vera in DED patients – **Simone Bruzio**

17.10 Possible use of exosomes for the ocular surface and periocular region – **Sandra Weinfurter**

17.18 Discussion

17.30 WORKSHOP MEDINOVA

17.30 New protocol Optilift microneedling device – **Paris Hatzianastasiadis**

17.50 My experience with Optilift clinical case – **Giovanni Tedesco**

18.10 Discussion



FRIDAY, JUNE 5

09.00 SESSION IV: DIAGNOSTIC PLATFORMS

(Featured: Meibography, OCT, Tear Film Analysis, MOA)

Emerging technologies for ocular surface evaluation and tear film assessment.

MODERATORS: **Marco Zeppieri, Fedele Russo**

PANEL: **Anna Maria Roszkowska, Jesus Merayo, Anoud Al-Saati, Samer Hamada, Liliana Nobrega**

09.00 Tfos Dews III: new evidence in the literature on the dry eye
– **Luca D'Andrea**

09.08 Conjunctival Microvilli: A Critical Indicator of Early Ocular
Surface Dysfunction – **Mario Troisi**

09.16 Automated measurement vs "human" measurement in tear
film analysis: is it time to change? Clinical study and literature
review – **Raffaele Piscopo**

09.24 Dry eye, Ocular surface pain and headaches. Could they be
related? – **Sònia Travé Huarte**

09.32 Inherited corneal dystrophies and dry eye – **Fabiana
D'Esposito**

09.40 Dupilumab-associated ocular surface disease - **Anna Maria
Roszkowska**



09.48 The effects of dysbiosis on surface disease and dry eye in children – **Samer Hamada**

09.56 Ultrastructural effects of tear substitutes on ocular surface epithelia – **Salvatore Troisi**

10.04 Discussion

10.21 SYMPOSIUM URSAPHARM

EVOLUTION OR REVOLUTION: PERFLUOROHXYLOCTANE THE CHAMPION OF THE DRY EYE

MODERATORS: **Giuseppe Giannaccare, Carlo Maria Santucci**

10.21 A record-breaking molecule in the dry eye – **Giuseppe Giannaccare**

10.36 Short- and long-term effects of a lipid substitute on signs and symptoms – **Carlo Maria Santucci**

10.51 Discussion

10.56 WORKSHOP GMV and COFFEE BREAK

11.26 Blepharitis as a Systemic Ocular Surface Disorder: From Brazilian Consensus to Integrated Clinical Excellence – **Liliana Nobrega**

11.34 The Dry Anophthalmic Socket Syndrome: Dry Eye in Patients Wearing Prostheses – **Alessandra Modugno**

11.42 The rule of Mucins in dry eye – **Jesus Merayo**

11.50 Diagnosis as dry eye but they are not – **Anoud Al-Saati**



11.58 Deep learning-based analysis of corneal plexus ivcm images
– **Antonio Fratini**

12.06 An Integrated Therapeutic Approach in Cataract Surgery:
Optimizing Topical Treatments and Ocular Surface Health Today to
Protect Tomorrow – **Giuseppe Giannaccare**

12.14 Discussion

12.30 SYMPOSIUM ESPANSIONE

REDEFINING OCULAR SURFACE DISEASE MANAGEMENT: THE ROLE OF LM™ LLLT PHOTOBIO-MODULATION

MODERATORS: **Giovanni Tedesco, Luca Vigo**

12.30 Photobiomodulation in Dry Eye Disease: From Biological
Mechanisms to Clinical Evidence – **Jennifer P. Craig**

12.45 Integrating Photobiomodulation into Ocular Surface Care:
Expanding Therapeutic Applications – **Carmela Sannace**

13.00 Optimizing Cataract and Refractive Surgery Outcomes: The
Role of Photobiomodulation in Real-World Practice – **Davide
Borroni**

13.15 Discussion

13.30 BREAK



14.00 SESSION V:

PARASURGICAL AND SURGICAL THERAPY

Innovative energy-based treatments, IPL, RF, LLLT, LipiFlow, QMR, and surgical management of severe DED.

MODERATORS: **Luca Vigo, Antonio Pascotto**

PANEL: **Carlo Orione, Ana Hervas, Paolo Fogagnolo, Luigi Marino, Jennifer P. Craig, Romina Fasciani**

14.00 Efficacy of Low-Level Light Therapy in Combination with Topical Non-Steroidal Immunosuppressants for the Treatment of Dry Eye Disease – **Davide Borroni**

14.08 Electroporation-Guided Biostimulation with PRP: A Regenerative Strategy for Severe Ocular Surface Disease – **Meriem Harouch**

14.16 Rosacea-associated MGD: clinical characteristics and meibography features – **Samer Hamada**

14.24 New developments in the treatment of blepharitis – **Carlo Orione**

14.32 The long-term results of IRPL in refractory MGD – **Paolo Fogagnolo**

14.40 The use of insulin in neurotrophic keratopathies – **Romina Fasciani**

14.48 Vitreo-retinal surgery and dry eye – **Gregorio Lo Giudice**

14.56 SLT a valid help for glaucomatous dry eye – **Federica Gualdi**

15.04 Meibomian gland dysfunction. Current diagnostic approach and new targeted therapies – **Ana Hervas**

15.12 The management of eye redness in the dry eye – **Fedele Russo**



15.20 Dry Eye in gamers: possible treatments – **Andres Benatti**

15.28 Gravity: The Unmet consideration in the Dry eye Treatment Algorithm – **Giovanni Tedesco**

15.36 Discussion

15.56 WORKSHOP FIMAS and COFFEE BREAK

MEET THE EXPERT: Giovanni Tedesco

16.26 High-Tech Diagnostics: Technology And Artificial Intelligence Redefining Standards In Dry Eye Disease – **Luigi Marino**

16.34 LLLT photobiomodulation therapy: expanding the therapeutic landscape of ocular surface care – **Jennifer P. Craig**

16.42 Choice of IOL in patients with dry eye – **Domenico Boccuzzi**

16.50 QMR in Neuropathic Corneal Pain: Corneal Nerve regeneration – **Andres Benatti**

16.58 Silk proteins + cross-linked CMC: a case series that opens up new treatment horizons for corneal surgery – **Romina Fasciani**

17.06 Improving ocular surface optimizing tear film clearance – **Luca Vigo**

17.14 Innovative systems & targeted nutrition for dry eye treatment – **Laura Castellini**

17.22 Discussion

17.45 WORKSHOP E-SWIN

WITH LIVE PATIENT EXPERIENCE AND NEW MODALITIES IN PATIENT DRY EYE MANAGEMENT



ROUND TABLE: **Liliana Nobrega, Luca Vigo, Anoud Al-Saati, Cristina Patricia Pac, Paolo Fogagnolo**

SATURDAY, JUNE 6

09.00 SESSION VI: MEDICAL THERAPY

Advances in pharmacological and biological treatments for ocular surface diseases. From anti-inflammatory approaches to regenerative and neuroprotective strategies.

MODERATORS: **Samer Hamada, Caterina Gagliano**

PANEL: **Pedram Hamrah, Viktor Perez, Anat Galor, Jesus Merayo, Mayte Ariño, Paolo Fogagnolo, Mina Massaro Giordano**

09.00 How to optimize the repair of the corneal epithelium –

Gianpaolo Carlini

09.08 Corneal and ocular surface biomechanical evaluation: the contribution of Corvis ST – **Giovanni Tedesco**

09.16 Autologous serum for the treatment of grade 2 and 3 neurotrophic keratitis: 1 year follow up – **Silvio Zuccarini, Simone Alex Bagaglia**

09.24 NCP (neuropathic corneal pain) – **Pedram Hamrah**

09.32 Cornea re-innervation with topical treatment – **Mayte Ariño**

09.40 Management of neurodeprivative DED – **Alfonso Strianese**



- 09.48 Corneal neurotization, DED and NK – **Paolo Fogagnolo**
- 09.56 What's new in dry eye – **Mina Massaro Giordano**
- 10.04 Use of Hemoderivatives in Neuropathic Pain and Beyond – **Viktor Perez**
- 10.12 Prevention of Regeneration of the ocular surface in severe dry eye with plasma rich in growth factors – **Jesus Merayo**
- 10.20 Neuroinflammation and its dry eye therapy – **Giulio Ferrari**
- 10.28 Esthesiometry and diabetes – **Manuel Caro Magdaleno**
- 10.36 Study presentation of the value of clinical use of esthesiometry in various ocular diseases – **Douglas K. Devries**
- 10.44 Ocular microbiome and probiotics – **Anat Galor**
- 10.52 High Tech vs Low Tech: technologies compared to detect the effects among tear substitutes – **Alfonso Strianese**
- 11.00 In Vivo Confocal Microscopy in Dry Eye and Ocular Surface Disease: A Practical Overview – **Maria Laura Passaro**
- 11.08 When the eye speaks to the immune system: synergy between rheumatologist and ophthalmologist – **Luca Cimino**
- 11.16 What to do in case of cataract surgery in the pc. Suffering from pemfigoid – **Giulio Ferrari**
- 11.24 Dry Eye in Patients with Glaucoma: What Do We Know and Management Strategies – **Valentino de Ruvo**
- 11.32 The clinical reproducibility of High-Tech instruments in DED – **Antonio Vagnoni**
- 11.40 Thyroid ophthalmopathy and dry eye – **Sofia Lunardon**
- 11.48 Variations in tear osmolarity and ocular surface after glaucoma surgery: a 3-month prospective study – **Luigi Peci**
- 11.56 Recurrent corneal erosions – **Maria Gessa**
- 12.04 AI and the dry eye patient journey – **Liz Barrett**



12.12 Discussion

12.30 CLOSING OF THE CONGRESS

JUNE 4-6, 2016

NAPLES, ITALY
CENTRO CONGRESSI STAZIONE MARITTIMA

WITH THE PARTICIPATION OF
DrySpa®


5TH INTERNATIONAL DRY EYE CONGRESS

A WORLD OF INNOVATION FOR THE OCULAR SURFACE

ORGANIZZERS:
Luca Vigo, Giovanni Nebbio
PRESIDENT:
Prof. Carlo Donatelli,
Prof. Francesca Simonelli
SCIENTIFIC COMMITTEE:
Andrea Baccini, Paolo Fogagnolo,
Caterina Gagliano, Samir Hamada,
Mira Massimo, Giordano Desimo Mazzotta,
Antonio Marzavigna, Lina Nibbrig,
Dario Rocha De Lencastre, Roberto Teyss

L'ecosistema tecnologico del dry eye

Mapa a 3 livelli delle tecnologie diagnostiche e terapeutiche, organizzate per driver eziologici.



ACRONIMI

NIBUT: Non-Invasive Break-Up Time. **TMH**: Tear Meniscus Height. **MGD**: Meibomian Gland Dysfunction. **IPL**: Intense Pulsed Light. **LLLT**: Low-Level Light Therapy (photobiomodulation). **QMR**: Quantum Molecular Resonance. **POC**: Point-of-Care. **MMP-9**: Matrix Metalloproteinase-9. **IA**: Intelligenza Artificiale. **IVCM**: In-Vivo Confocal Microscopy. **TRPM8**: Transient Receptor Potential Melastatin 8. **siRNA**: small interfering RNA. **RASP**: Reactive Aldehyde Species (aldehyde-trapping target). **SFA**: Semi-Fluorinated Alkane (lipid-only, water-free eye drop vehicle; e.g., perfluorohexyloctane). Disclaimer: Le tecnologie riportate rappresentano una selezione esemplificativa e non esaustiva; per ragioni di sintesi grafica non sono state incluse tutte le opzioni diagnostiche e terapeutiche disponibili o in sviluppo.

Fonti: Tear Film & Ocular Surface Society DEWS II (2017) e DEWS III (2025) reports.